Literature DB >> 29296955

Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.

Bronwen E Shaw1.   

Abstract

Publisher's Note: This article has a companion Point by Fuchs. Publisher's Note: Join in the discussion of these articles at Blood Advances Community Conversations.

Year:  2017        PMID： 29296955      PMCID： PMC5738987          DOI： 10.1182/bloodadvances.2016002188

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  56 in total

1.  Blood stem cell donation: a model for worldwide cooperation in transplantation.

Authors:  William Y K Hwang; Lydia M Foeken
Journal:  Ann Acad Med Singapore       Date:  2014-06       Impact factor: 2.473

2.  Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index.

Authors:  Asad Bashey; Xu Zhang; Katelin Jackson; Stacey Brown; Michelle Ridgeway; Melhem Solh; Lawrence E Morris; H Kent Holland; Scott R Solomon
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-07       Impact factor: 5.742

3.  High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Authors:  Leo Luznik; Javier Bolaños-Meade; Marianna Zahurak; Allen R Chen; B Douglas Smith; Robert Brodsky; Carol Ann Huff; Ivan Borrello; William Matsui; Jonathan D Powell; Yvette Kasamon; Steven N Goodman; Allan Hess; Hyam I Levitsky; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

4.  Peripheral-blood stem cells versus bone marrow from unrelated donors.

Authors:  Claudio Anasetti; Brent R Logan; Stephanie J Lee; Edmund K Waller; Daniel J Weisdorf; John R Wingard; Corey S Cutler; Peter Westervelt; Ann Woolfrey; Stephen Couban; Gerhard Ehninger; Laura Johnston; Richard T Maziarz; Michael A Pulsipher; David L Porter; Shin Mineishi; John M McCarty; Shakila P Khan; Paolo Anderlini; William I Bensinger; Susan F Leitman; Scott D Rowley; Christopher Bredeson; Shelly L Carter; Mary M Horowitz; Dennis L Confer
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

5.  Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization.

Authors:  J Pidala; J Kim; M Schell; S J Lee; R Hillgruber; V Nye; E Ayala; M Alsina; B Betts; R Bookout; H F Fernandez; T Field; F L Locke; T Nishihori; J L Ochoa; L Perez; J Perkins; J Shapiro; C Tate; M Tomblyn; C Anasetti
Journal:  Bone Marrow Transplant       Date:  2012-08-06       Impact factor: 5.483

6.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.

Authors:  Anna Maria Raiola; Alida Dominietto; Carmen di Grazia; Teresa Lamparelli; Francesca Gualandi; Adalberto Ibatici; Stefania Bregante; Maria Teresa Van Lint; Riccardo Varaldo; Anna Ghiso; Marco Gobbi; Angelo Michele Carella; Alessio Signori; Federica Galaverna; Andrea Bacigalupo
Journal:  Biol Blood Marrow Transplant       Date:  2014-06-05       Impact factor: 5.742

7.  Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

Authors:  Abraham S Kanate; Alberto Mussetti; Mohamed A Kharfan-Dabaja; Kwang W Ahn; Alyssa DiGilio; Amer Beitinjaneh; Saurabh Chhabra; Timothy S Fenske; Cesar Freytes; Robert Peter Gale; Siddhartha Ganguly; Mark Hertzberg; Evgeny Klyuchnikov; Hillard M Lazarus; Richard Olsson; Miguel-Angel Perales; Andrew Rezvani; Marcie Riches; Ayman Saad; Shimon Slavin; Sonali M Smith; Anna Sureda; Jean Yared; Stefan Ciurea; Philippe Armand; Rachel Salit; Javier Bolaños-Meade; Mehdi Hamadani
Journal:  Blood       Date:  2015-12-15       Impact factor: 22.113

8.  Loss of Mismatched HLA on the Leukemic Blasts of Patients With Relapsed Lymphoid Malignancies Following Bone Marrow Transplantation From Related Donors With HLA Class II Mismatches in the Graft Versus Host Direction.

Authors:  Koichi Hirabayashi; Takashi Kurata; Kazuki Horiuchi; Shoji Saito; Tomonari Shigemura; Miyuki Tanaka; Ryu Yanagisawa; Kazuyuki Matsuda; Kazuo Sakashita; Kenichi Koike; Yozo Nakazawa
Journal:  Pediatr Blood Cancer       Date:  2015-11-06       Impact factor: 3.167

9.  Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide.

Authors:  Luca Castagna; Roberto Crocchiolo; Sabine Furst; Stefania Bramanti; Jean El Cheikh; Barbara Sarina; Angela Granata; Elisa Mauro; Catherine Faucher; Bilal Mohty; Samia Harbi; Christian Chabannon; Carmelo Carlo-Stella; Armando Santoro; Didier Blaise
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-13       Impact factor: 5.742

Review 10.  How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

Authors:  Ying-Jun Chang; Leo Luznik; Ephraim J Fuchs; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388
View more
  3 in total

1.  Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation.

Authors:  Jun Zou; Stefan O Ciurea; Piyanuch Kongtim; Min Yi; Yudith Carmazzi; Gabriela Rondon; Samer Srour; David Partlow; Richard E Champlin; Kai Cao
Journal:  Blood Adv       Date:  2020-08-11

2.  National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.

Authors:  Bronwen E Shaw; Antonio Martin Jimenez-Jimenez; Linda J Burns; Brent R Logan; Farhad Khimani; Brian C Shaffer; Nirav N Shah; Alisha Mussetter; Xiao-Ying Tang; John M McCarty; Asif Alavi; Nosha Farhadfar; Katarzyna Jamieson; Nancy M Hardy; Hannah Choe; Richard F Ambinder; Claudio Anasetti; Miguel-Angel Perales; Stephen R Spellman; Alan Howard; Krishna V Komanduri; Leo Luznik; Maxim Norkin; Joseph A Pidala; Voravit Ratanatharathorn; Dennis L Confer; Steven M Devine; Mary M Horowitz; Javier Bolaños-Meade
Journal:  J Clin Oncol       Date:  2021-04-27       Impact factor: 50.717

3.  Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults.

Authors:  Heather J Symons; Marianna Zahurak; Yilin Cao; Allen Chen; Kenneth Cooke; Christopher Gamper; Orly Klein; Nicolas Llosa; Elias T Zambidis; Richard Ambinder; Javier Bolaños-Meade; Ivan Borrello; Robert Brodsky; Amy DeZern; Ivana Gojo; Margaret Showel; Lode Swinnen; B Douglas Smith; Leo Luznik; Richard J Jones; Ephraim J Fuchs
Journal:  Blood Adv       Date:  2020-08-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.